Mochida Pharmaceutical Co.,Ltd.(4534) News

Announcement of Partnership Agreement for the Biosimilar of Follitropin Alfa

[Summary] Notice Concerning Determination of Offering Price and Other Matters

Launch of “Avarept Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition

Announcement of a Partnership Agreement for Dinagest in South Korea and Thailand

Mochida Pharma continues decline on concerns over supply-demand deterioration from share offering

Notice Regarding the Succession of Manufacturing and Marketing Approval and Asset Acquisition of URECE Tablets

Notice Regarding Resolution on Share Repurchase

[Summary] Notice Regarding Secondary Offering of Shares

Consolidated Financial Results for the Nine Months Ended December 31, 2025(Under Japanese GAAP)(Completion of Interim Review by an Independent Auditor

Announcement of Manufacturing and Marketing Approval for Tocilizumab BS MA in Japan

[Summary] Consolidated Financial Results for the Nine Months Ended December 31, 2025

Mochida Pharma, Ordinary Profit Forecast for the Fiscal Year Revised Upward to an Unexpected 36% Increase

Announcement of the Establishment of Mochida Medical USA, Inc.

Notice Concerning Revisions to Full-Year Consolidated Financial Results Forecasts

Obtained manufacturing and marketing approval in Japan for Avarept Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient

Driven by a common vision, Mochida Pharmaceutical Co., Ltd. and Duchesnay Inc. sign a partnership to help address the issue of drug gap in Japan

[Summary] Consolidated Financial Results for the Six Months Ended September 30, 2025

Mochida Pharma, First Half Ordinary Profit Increases by 27%, Jul-Sep Ordinary Profit Increases by 40%

Notice Concerning Subscription to a Third-Party Allotment of Shares and the Acquisition of Shares of And Pharma Co., Ltd.

[Summary] Consolidated Financial Results for the Three Months Ended June 30, 2025